Vanguard Group Inc. Has $156.44 Million Position in Pediatrix Medical Group, Inc. $MD

Key Points

• Vanguard Group Inc. currently holds a stock position worth $156.44 million in Pediatrix Medical Group, Inc., owning approximately 12.58% of the company after a slight decrease of 0.1% in shares.
• Pediatrix Medical Group recently reported an earnings per share (EPS) of $0.53, surpassing expectations of $0.42, even as quarterly revenue declined by 7.1% year-over-year.
• Analysts have given Pediatrix Medical Group a consensus rating of "Moderate Buy", with price targets ranging from $16.50 to $20.00.

Vanguard Group Inc. decreased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 0.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,796,650 shares of the company's stock after selling 15,961 shares during the quarter. Vanguard Group Inc. owned approximately 12.58% of Pediatrix Medical Group worth $156,443,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in MD. Oberweis Asset Management Inc. bought a new position in shares of Pediatrix Medical Group in the 4th quarter valued at about $6,122,000. Nomura Holdings Inc. acquired a new position in Pediatrix Medical Group during the fourth quarter valued at approximately $3,882,000. Nuveen Asset Management LLC boosted its position in Pediatrix Medical Group by 110.8% during the fourth quarter. Nuveen Asset Management LLC now owns 485,587 shares of the company's stock valued at $6,371,000 after purchasing an additional 255,273 shares during the last quarter. Raymond James Financial Inc. bought a new position in Pediatrix Medical Group in the fourth quarter valued at approximately $3,066,000. Finally, Teacher Retirement System of Texas increased its position in shares of Pediatrix Medical Group by 92.3% during the 1st quarter. Teacher Retirement System of Texas now owns 371,756 shares of the company's stock worth $5,387,000 after purchasing an additional 178,386 shares during the last quarter. Institutional investors own 97.71% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Macquarie increased their price objective on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Zacks Research raised shares of Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. Finally, UBS Group boosted their price objective on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Pediatrix Medical Group has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.

Pediatrix Medical Group Stock Performance

NYSE MD traded down $0.05 on Tuesday, reaching $17.01. The stock had a trading volume of 811,712 shares, compared to its average volume of 911,081. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. The company has a market cap of $1.48 billion, a P/E ratio of 13.19 and a beta of 1.21. The firm has a fifty day moving average of $13.90 and a two-hundred day moving average of $13.98. Pediatrix Medical Group, Inc. has a 1-year low of $10.06 and a 1-year high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.11. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The company had revenue of $468.84 million during the quarter, compared to analysts' expectations of $464.37 million. During the same quarter in the previous year, the business posted $0.34 earnings per share. Pediatrix Medical Group's quarterly revenue was down 7.1% on a year-over-year basis. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.